AllRock Bio is a clinical-stage biotechnology company focused on advancing therapies for cardiopulmonary and fibrotic diseases. The company's lead candidate, ROC-101, is a first-in-class, oral pan-ROCK inhibitor being developed to address the urgent unmet need in pulmonary arterial hypertension (PAH) and other life-threatening fibrotic diseases. With a seasoned leadership team and a commitment to addressing unmet need, AllRock is dedicated to bringing a new class of disease-modifying therapies to patients.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/16/25 | $50,000,000 | Series A |
Versant Ventures Westlake BioPartners | undisclosed |
